At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
Today’s New York Times had an article written by Jane Brody that discusses the painful issues surrounding the decision to stop treatment, and its negative side effects, and let a cancer survivor live their last weeks in relative peace. This is always a difficult decision as many of us wish to hold on to life, [...]
Last April HealthDay News ran an article about chemotherapy and patients fear about starting it. Most cancer survivors involved in a recent survey reported that they had been fearful of undergoing chemotherapy. The good news is that most also said the treatments were much less difficult than they had expected. The truly startling fact is [...]
You are scheduled for chemotherapy (Taxotere if you are being treated for prostate cancer) in a few days, so you stop eating until you complete the therapy session! This scenario could become typical in future treatment protocols. Published last week in Proceedings of the National Academy of Sciences was a study that found that starving [...]
During radiation and chemotherapy, cancer patients including prostate cancer patients, should avoid the routine use of antioxidant supplements unless approved by their doctor. Supplements may reduce the anticancer benefits of therapy, researchers concluded in a commentary published online in the Journal of the National Cancer Institute. Radiation and Taxotere used for advanced prostate cancer therapy [...]